Advanced search
Publication Cover
Infection Ecology & Epidemiology Volume 5, 2015 - Issue 1
Submit an article Journal homepage
598
Views
2
CrossRef citations to date
0
Altmetric
Original Research Articles

A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases

Anna-Karin JonssonSection of Infectious Diseases Department of Medical Sciences, Uppsala University, Uppsala, Sweden
, MD,
Anders LarssonDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
(Professor) ,
Thomas TängdénSection of Infectious Diseases Department of Medical Sciences, Uppsala University, Uppsala, Sweden
, MD, PhD,
Åsa MelhusDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
(Associate Professor) &
Anders LannergårdSection of Infectious Diseases Department of Medical Sciences, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
, MD, PhD
Article: 28224 | Received 14 Apr 2015, Accepted 15 Oct 2015, Published online: 09 Nov 2015

References

  • Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8: 159–66.
  • Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004; 42: 4769–75.
  • Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev. 2013; 26: 744–58.
  • Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother. 2010; 54: 3564–8.
  • Tham J, Odenholt I, Walder M, Brolund A, Ahl J, Melander E. Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers’ diarrhoea. Scand J Infect Dis. 2010; 42: 275–80.
  • Lytsy B, Sandegren L, Tano E, Torell E, Andersson DI, Melhus A. The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15. APMIS. 2008; 116: 302–8.
  • Ransjo U, Lytsy B, Melhus A, Aspevall O, Artinger C, Eriksson BM, etal. Hospital outbreak control requires joint efforts from hospital management, microbiology and infection control. J Hosp Infect. 2010; 76: 26–31.
  • Tangden T, Eriksson BM, Melhus A, Svennblad B, Cars O. Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011; 66: 1161–7.
  • Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol. 2012; 7: 1173–89.
  • Titelman E, Hasan CM, Iversen A, Nauclér P, Kais M, Kalin M, etal. Faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors. Clin Microbiol Infect. 2014; 20: O508–15.
  • Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003; 35: 433–40.
  • Nilsson E, Larsson A, Olesen HV, Wejaker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol. 2008; 43: 892–9.
  • Sarker SA, Casswall TH, Juneja LR, Hoq E, Hossain I, Fuchs GJ, etal. Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 2001; 32: 19–25.
  • Rahman S, Van Nguyen S, Icatlo FC Jr, Umeda K, Kodama Y. Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases. Hum Vaccin Immunother. 2013; 9: 1039–48.
  • Warr GW, Magor KE, Higgins DA. IgY: clues to the origins of modern antibodies. Immunol Today. 1995; 16: 392–8.
  • Akita EM, Nakai S. Immunoglobulins from egg-yolk – isolation and purification. J Food Sci. 1992; 57: 629–34.
  • Akita EM, Li-Chan EC. Isolation of bovine immunoglobulin G subclasses from milk, colostrum, and whey using immobilized egg yolk antibodies. J Dairy Sci. 1998; 81: 54–63.
  • Birgand G, Armand-Lefevre L, Lolom I, Ruppe E, Andremont A, Lucet JC. Duration of colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae after hospital discharge. Am J Infect Contr. 2013; 41: 443–7.
  • Cook SR, Maiti PK, DeVinney R, Allen-Vercoe E, Bach SJ, McAllister TA. Avian- and mammalian-derived antibodies against adherence-associated proteins inhibit host cell colonization by Escherichia coli O157:H7. J Appl Microbiol. 2007; 103: 1206–19.
  • Thomsen K, Christophersen L, Bjarnsholt T, Jensen PO, Moser C, Hoiby N. Anti-Pseudomonas aeruginosa IgY antibodies induce specific bacterial aggregation and internalization in human polymorphonuclear neutrophils. Infect Immun. 2015; 83: 2686–93.
  • Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, etal. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immunol. 2002; 9: 1061–6. [PubMed Abstract] [PubMed CentralFull Text].

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.